# Antibacterial Resistance Leadership Group (ARLG)

> **NIH NIH UM1** · DUKE UNIVERSITY · 2020 · $14,943,650

## Abstract

Our goal is to continue to advance the successful, multidisciplinary research agenda of the Antibacterial
Resistance Leadership Group (ARLG). In the original award period, the ARLG agenda increased scientific
knowledge of antibacterial resistance and sought to mitigate important factors that drive its expansion. We
continue to pair an unprecedented team of over two dozen of the world's top investigators with the
organizational excellence of the Duke Clinical Research Institute (DCRI), one of the world's largest Academic
Research Organizations. Because of the complexity of integrating multiple components of such a large-scale
clinical research network, our renewal continues to feature centralized leadership through an Executive
Committee and a dual PI approach. One PI (Fowler) focuses primarily on operations and the other (Chambers)
focuses largely on scientific agenda. The organizational structure also features Scientific Subcommittees
devoted to three priority areas: Gram-negative bacterial infections, Gram-positive bacterial infections, and
Diagnostics. These Subcommittees are supported by internationally recognized Collaborating Investigators to
advance four core value areas: 1) Scientific Expertise; 2) Innovations; 3) Mentoring and Diversity; and 4)
Network Development. To complement the ongoing research activities of both the diagnostic and the
pharmaceutical industries, our ARLG has established collaborative ties with members of both communities.
Our long-term research goal is to improve outcomes of multiple-drug resistant (MDR) bacterial infections by
designing and conducting transformational diagnostic and therapeutic clinical trials. Our research portfolio will
pursue this goal in therapeutics by conducting first-in kind strategy trials in MDR Gram-negative bacteria and
MRSA and by studying nontraditional therapeutics (monoclonal antibodies and bacteriophages) against MDR
Pseudomonas aeruginosa. We will pursue this goal in diagnostics by obtaining FDA approval for a host gene
expression-based diagnostic and by evaluating the clinical impact of rapid phenotypic testing in patients with
bloodstream infection. Our research agenda reflects a realistic strategy of incremental steps towards complex
practice-changing trials. Our Specific Aims are to 1) To maintain a Scientific Leadership Center (SLC) that
provides overall scientific and administrative leadership for the network; 2) To maintain a Clinical Operations
Center (COC) that provides operational support, management, and oversight for the network’s clinical studies
and trials; 3) To maintain a Laboratory Center (LC) that advances the ARLG research agenda by leading the
development, implementation, and evaluation of essential laboratory research; and 4): To maintain a Statistics
and Data Management Center (SDMC) that advances the ARLG research agenda by providing leadership in
biostatistics, study design, analysis, interpretation, and publication of results. By advancing these specific
ai...

## Key facts

- **NIH application ID:** 9841607
- **Project number:** 2UM1AI104681-08
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Vance G. Fowler
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $14,943,650
- **Award type:** 2
- **Project period:** 2013-06-01 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9841607

## Citation

> US National Institutes of Health, RePORTER application 9841607, Antibacterial Resistance Leadership Group (ARLG) (2UM1AI104681-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9841607. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*